CAJ | 학술논문

目的：探讨螺内酯联合福辛普利治疗2型糖尿病肾病的安全性及其对蛋白尿的影响。方法：60位2型糖尿病肾病患者随机平均分为对照组和治疗组，对照组予福辛普利10mg?d-1治疗，治疗组额外予螺内酯20mg?d-1治疗，实验持续12周，定期测量患者血压、生化指标及24h尿蛋白定量。结果：与对照组比较，治疗组24h尿蛋白下降更显著（P<0.01），患者没有明显导致肾小球滤过率（GFR）下降、血钾上升及低血压。结论：一定剂量的螺内酯能加强血管紧张素转化酶抑制剂（ACEIs）对糖尿病肾病进程延缓作用。
목적：탐토라내지연합복신보리치료2형당뇨병신병적안전성급기대단백뇨적영향。방법：60위2형당뇨병신병환자수궤평균분위대조조화치료조，대조조여복신보리10mg?d-1치료，치료조액외여라내지20mg?d-1치료，실험지속12주，정기측량환자혈압、생화지표급24h뇨단백정량。결과：여대조조비교，치료조24h뇨단백하강경현저（P<0.01），환자몰유명현도치신소구려과솔（GFR）하강、혈갑상승급저혈압。결론：일정제량적라내지능가강혈관긴장소전화매억제제（ACEIs）대당뇨병신병진정연완작용。
Objective: To investigate the safety of combined therapy of spironolactone and fosinopril in the treatment of type 2 diabetic nephropathy and its effect on proteinuria. Methods: Sixty patients with type 2 diabetic nephropathy were randomly devided into control group and case group. Patients in the control group received fosinopril (10mg/d) and those in the case group received additional spironolactone (20mg/d) for 12 weeks. Blood pressure, biochemical parameters and 24-h proteinuria were determined for each patient at regular intervals. Results:24-h proteinuria reduced more signiifcantly in the case group compared to the control group (P<0.01), the patients did not develop any signiifcant adverse effect including distinct reduction in GFR, hyperkalemia and hypotension. Conclusion: Low to moderate doses of spironolactone can augment the effect of ACEIs in the prevention of diabetic nephropathy.